

Date Mailed: March 28, 2000

09/509449

Sheet 1 of 1

416 Rec'd PCT/PTO

28 MAR 2000

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 594.352USWO		Application Number: Unknown
	Applicant: AOYAGI, et al.		
	Filing Date: March 28, 2000		Group Art Unit: Unknown


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>Q</i>	5,616,460	April 1, 1997	Steve FIGARD	<u> </u>	<u> </u>	6/1995	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>Q</i>	JP 8-5633 A	Jan. 12, 1996	Japan	<u> </u>	<u> </u>		X
<i>Q</i>	JP 60-24451 A	Feb. 7, 1985	Japan	<u> </u>	<u> </u>		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>Q</i>		International Search Report dated October 4, 1999, prepared by JPO

EXAMINER <i>Q</i>	DATE CONSIDERED <i>7/25/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 594.352USWO	Application Number: 09/509449
	Applicant: AOYAGI et al.	
	Filing Date: March 28, 2000	Group Art Unit: 1643 <i>1648</i>



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>12</i>	JP 11-108932	April 23, 1999	Japan	—	—	Abstract	
<i>12</i>	JP 06-38765	Feb. 15, 1994	Japan	—	—	Abstract	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>12</i>		Higa. "Calcium-dependent Bacteriophage DNA Infection," <i>Letters to the Editor, Journal of Molecular Biology</i> , Vol. 53 (1970): pp. 159-162.					
<i>12</i>		Kohler et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , Vol. 256 (Aug. 7, 1975): pp. 495-497.					
<i>12</i>		Kohler et al. "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>European Journal of Immunology</i> , Vol. 6 (1976): pp. 511-519.					
<i>12</i>		Chiba et al. "Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus," <i>Proc. National Academy of Science</i> , Vol. 88 (June 1991): pp. 4641-4645.					
<i>12</i>		Takahashi et al. "Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts," <i>Journal of General Virology</i> , Vol. 73 (1992): pp. 667-672.					
<i>12</i>		Sang. <i>Enhanced Sensitivity of a Second Generation ELISA for Antibody to Hepatitis C Virus</i> . 1992, pp. 213-217.					
<i>12</i>		Okamoto et al. "Antibodies Against Synthetic Oligopeptides Deduced from the Putative Core Gene for the Diagnosis of Hepatitis C Virus Infection," <i>Hepatology</i> , Vol. 15, No. 2 (1992): pp. 180-186.					
<i>12</i>		Sallberg et al. "Immunodominant Regions within the Hepatitis C Virus Core and Putative Matrix Proteins," <i>Journal of Clinical Microbiology</i> , Vol. 30, No. 8 (Aug. 1992): pp. 1989-1994.					
<i>12</i>		Machida et al. "Two Distinct Subtypes of Hepatitis C Virus Defined by Antibodies Directed to the Putative Core Protein," <i>Hepatology</i> , Vol. 16, No. 4 (1992): pp. 886-891.					
<i>12</i>		Sallberg et al. "Locations of Antibody Binding Sites within Conserved Regions of the Hepatitis C Virus Core Protein," <i>Journal of Medical Virology</i> , Vol. 43 (1994): pp. 62-68.					
<i>12</i>		Kashiwakuma et al. "Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA)," <i>Journal of Immunological Methods</i> , Vol. 190 (1996): pp. 79-89.					
<i>12</i>		Hoogenboom. "Designing and optimizing library selection strategies for generating high-affinity antibodies," <i>Tibtech</i> , Vol. 15 (Feb. 1997): pp. 62-70.					
<i>12</i>		Weber et al. "Reduction of Diagnostic Window by New Fourth-Generation Human Immunodeficiency Virus Screening Assays," <i>Journal of Clinical Microbiology</i> , Vol. 36, No. 8 (Aug. 1998): pp. 2235-2239.					

EXAMINER <i>Q. C. [Signature]</i>	DATE CONSIDERED <i>9/25/01</i>	 23552 PATENT TRADEMARK OFFICE
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not considered. Include copy of this form for next communication to the Applicant.		